biomed devic servic
diagnost tool
price close busi may
diagnost tool
preview precis diagnost
ghdx grail guardant among
note lay key oral abstract poster session abstract
cancer diagnost display annual meet american
societi clinic oncolog largest oncolog confer world
attende attend chicago friday june tuesday june
theme year meet includ emerg target drug immuno-oncolog
therapi blood-bas cancer detect patient monitor liquid biopsi
companion diagnost role new tool improv care reduc cost
perus meet program highlight abstract present
relev precis medicin life scienc tool diagnost sector
believ enclos abstract use investor other engag next-
gener sequenc liquid biopsi companion diagnost
molecular epic scienc genoptix
genom health buy pt out-of-consensu buy ghdx work
see upsid ahead ghdx focus busi target meaning
profit ghdx lead act long-await data
tailorx studi accept late-break present
present sunday june buyer ahead data ghdx
expect posit futur oncotyp dx adopt us europ
grail privat grail present result abstract focus cell-fre
develop comprehens cell-fre dna cfdna assay earli detect
genome-wid sequenc earli stage lung cancer detect plasma cell-fre
preval clonal hematopoiesi indetermin potenti chip measur
ultra-sensit sequenc assay exploratori analysi circul cancer genom
addit primarili focu follow key compani
scienc freenom other exhibit expect presenc
freenom
prostat breast cancer grail ghdx epic
companion dx roch fmi nanostr epic scienc htg molecular
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
preview precis diagnost
ghdx grail
among highlight
note lay key oral abstract poster session abstract
cancer diagnost display annual meet
american societi clinic oncolog largest oncolog confer world
attende attend chicago friday june tue june
theme includ emerg target drug immuno-oncolog therapi
blood-bas cancer detect patient monitor liquid biopsi companion
diagnost role new tool improv care reduc cost
perus meet program lay notabl present
think help investor other engag companion diagnost liquid
biopsi applic next-gen sequenc
htg molecular epic scienc other
primarili focu follow key area
other expect moder presenc freenom
prostat breast cancer grail ghdx epic
companion dx roch fmi nanostr htg
privat held market leader liquid
biopsi cancer rais fund date guardant present
abstract relat circul tumor dna ctdna liquid biopsi test
oncologist list price order test
order time sinc launch set
ambiti achiev goal deploy test peopl year
grail privat grail present result abstract focus cell-fre
develop comprehens cell-fre dna cfdna assay earli detect
genome-wid sequenc earli stage lung cancer detect plasma cell-fre
preval clonal hematopoiesi indetermin potenti chip measur
ultra-sensit sequenc assay exploratori analysi circul cancer
genom health buy pt fresh strong start genom health
present long-await data tailorx studi accept late-
break present view tailorx lead catalyst increas
penetr adopt oncotyp dx breast test eu us
diagnost tool
oral poster present
foundat medicine- abstract character nsclc non-
genom abstract tailorx phase trial chemoendocrin therapi
versu endocrin therapi alon hormon receptor-posit node-
neg breast cancer intermedi prognosi recurr
guardant abstract opportun provid educ use
interpret liquid biopsi
foundat medicine- abstract landscap kinas rearrang kre
detect circul tumor dna ctdna
grail- abstract develop comprehens cell-fre dna cfdna assay
earli detect multipl tumor type circul cell-fre genom atla
diagnost tool
grail- abstract genome-wid sequenc earli stage lung cancer
detect plasma cell-fre dna cfdna circul cell-fre genom atla
grail abstract preval clonal hematopoiesi indetermin potenti
chip measur ultra-sensit sequenc assay exploratori analysi
abstract view via
highlight select notabl abstract
booth loxo oncolog booth
hub number precis medicin greenshoot spoke
get start set multi-year cycl rapid growth physician-
order prenat carrier screen test consumer-ord genet test
power genotyp whole-exom sequenc popul
sequenc studi run govern across globe tissue-bas cancer
test blood-bas cancer studi test liquid biopsi
inc loxo oncolog loxo announc mid-april global
strateg partnership develop commerci multi-gen panel broad
tumor profil result distribut next-gener sequenc base
companion diagnost cdx pan-canc indic co-develop
partnership seek approv version trusight tumor
companion diagnost cdx loxo oncolog larotrectinib target ntrk
gene fusion target ret gene alter across tumor type
detect clearanc ret variant plasma cell free dna cfdna
patient pt treat
background novel highly-select small molecul ret inhibitor
clinic develop pt advanc cancer harbor oncogen ret
papillari thyroid cancer cancer studi modul
ret variant allel frequenc af plasma cfdna therapi
method studi on-going phase studi pt
advanc solid tumor enrol enrich pt ret alter
blood collect pretreat day treatment
restag cfdna analysi next-gener sequenc guardant
result pt enrol ret fusion nsclc
ret-mut mtc dose bid plasma
diagnost tool
sampl collect report pt plasma result avail
pt enrol base ret variant detect tumor sampl
concord ret alter detect correspond pre-
treatment plasma sampl includ pt ret-fus nsclc
pt ret-mut mtc median af higher mtc
nsclc neg pre-treat sampl peak af detect
alter low median suggest low tumor dna shed plasma
pt detect pre-treat plasma ret alter day plasma
retalter af decreas median complet clearanc
pt day plasma clearanc observ multipl dose bid
common ret fusion-posit ret-mut pt data
addit pt updat time present
conclus rapid clearanc ret variant plasma cfdna
support observ clinic activ across rang dose tumor type
ret alter plasma cfdna detect rang
target ret variant though tumor genotyp remain critic initi plasma
neg serial plasma genotyp warrant continu studi earli
pharmacodynam marker novel target therapi clinic trial
grail mission detect cancer earli cure grail form
rais billion sinc incept short period time grail
launch two clinic trial circul cell-fre genom atla studi ccga
strive studi purpos circul cell-fre genom atla studi
ccga character landscap cell-fre nucleic acid cfna profil
individu without cancer purpos strive studi launch
april train valid test detect breast cancer train
develop pan-canc test detect multipl cancer earli stage grail
enrol particip population-scal clinic studi ccga
strive on-track complet enrol studi year grail
enrol goal ccga goal strive grail
releas data ccga studi mid-may present earli find
four abstract two oral present
develop comprehens cell-fre dna cfdna assay earli
detect multipl tumor type circul cell-fre genom atla
background global cancer detect advanc stage high
treatment burden low cure rate non-invasive cfdna blood test detect
multipl cancer earli stage cur treatment like succeed
desir ccga prospect multi-cent observ studi
develop non-invasive cfdna-bas multi-canc detect assay
method prospect collect sampl control cancer
diagnosi particip pt newli diagnos untreat cancer
tumor type stage analyz preplan substudi prototyp
sequenc assay perform pair cfdna white blood cell
target sequenc gene singl nucleotid variants/indel
pair cfdna whole genom sequenc wg copi number
variat cfdna whole genom bisulfit sequenc wgb methyl
assay detect model develop cancer pt sensit
estim specif
diagnost tool
result pt w/cancer similar age smoke statu gender wgb
highest sensit report result consist across assay
esophag head neck hepatobiliari
myeloma ovarian pancreat
breast cancer-specif assay result report separ cancer low signal
melanoma renal comparison tumor wg multi-assay classif
conclus cfdna-bas blood test detect multipl cancer variou stage
high specif indic approach promis multi-canc screen
test includ lethal unscreen cancer stage shift impact mortal
assay clinic develop multi-canc cfdna test
asymptomat popul on-going clinic trial inform
background new breast cancer screen approach need detect clinic
aggress subtyp may detect mammographi detect late
unscreen popul ccga prospect multi-cent
observ studi develop non-invasive assay cancer detect
preplan substudi women-onli cohort report
method blood prospect collect particip pt
newli diagnos untreat cancer tumor type stage pt
cancer diagnosi control plasma cfdna extract substudi includ
pt invas breast cancer ibc three prototyp sequenc
assay perform pair cfdna white blood cell target sequenc
gene singl nucleotid variants/indel pair cfdna
whole genom sequenc wg copi number variat cfdna whole
genom bisulfit sequenc wgb methyl sequenc identifi
contribut clonal hematopoiesi ch assay classif model
use cross-valid develop discrimin ibc use
subset women sensit estim specif
result ibc pt similar age mean yrssd ibc
ibc pt symptomat subset document interv cancer
stage i/ii subtyp breakdown breast cancer
tnbc wgb return highest sensit assay
report result consist across assay sensit ci
higher tnbc vs vs vs vs
higher symptomat vs screen-detect breast cancer
vs comparison tumor wg multi-assay classif
conclus breast cancer detect cfdna signal time diagnosi
includ clinic aggress subtyp symptomat present assay
clinic develop intend use popul on-going
diagnost tool
preval clonal hematopoiesi indetermin potenti chip
measur ultra-sensit sequenc assay exploratori analysi
background chip defin presenc age-depend acquir mutat
hematopoiet progenitor cell report occur
individu year age chip risk factor hematolog malign
cardiovascular diseas biolog mechan clinic signific
studi use assay sensit exom sequenc
determin preval featur chip ccga cohort impact
interpret cell-fre dna cfdna somat variant
method blood prospect collect control cancer
 particip pt newly-diagnos untreat cancer tumor type
stage cfdna isol pair white blood cell cfdna
nucleotid variants/indel uniqu molecular barcod machin learning-bas
nois model achiev specif fals posit variant call per mb genom
target limit detect variant allel frequenc vaf
result sampl elig evalu pt solid tumor
type stage somat cfdna variant match chip individu
chip vaf chip vaf nearli pt
somat mutat vaf rate similar pt median
age increas preval per decad observ
variants/mb age chip variant identifi uniqu individu
patient present low vaf gene impact chip
includ consist previou
report patient solid tumor
conclus ultra-sensit sequenc assay demonstr chip signal
cfdna much common previous appreci clinic
signific chip warrant studi must account
interpret cfdna variant earli cancer detect tumor genotyp
genome-wid sequenc earli stage lung cancer detect plasma
full final text abstract post on-line et sat june
ghdx eagerli await present tailorx studi accept
late-break present june tailorx larg prospect
random clinic trial design precis defin effect chemotherapi
benefit lack therefor women consid intermedi risk
recurr base oncotyp dx test result score view tailorx
lead catalyst increas penetr adopt oncotyp dx breast
test eu us manag call indic us
expect present data posit regardless particular cut-off
tailorx phase trial chemoendocrin therapi versu endocrin therapi
alon hormon receptor-posit node-neg breast
cancer intermedi prognosi recurr score
full final text abstract post on-line et sun june
diagnost tool
long-term outcom women low-risk hormone-sensit early-stag
background oncotyp dx test use identif women low
risk recurr safe avoid chemotherapi howev persist
gap knowledg use oncotyp test treatment decis minim
harm maxim benefit chemotherapi among women favor
prognosi breast cancer evalu long-term outcom women diagnos
early-stag node neg hormon receptor posit breast cancer oncotyp
score use establish cancer intervent surveil model
method mont carlo microsimul conduct project long-term
year outcom first event recurr distant recurr all-caus
mortal among women diagnos neg er posit nodeneg
breast cancer tumor cm oncotyp score input
paramet deriv oxford overview publish nsabp trial data
assess model valid compar kaplan-mei surviv estim
trial endpoint trial assign individu option treatment
result women favor gene-express profil high recurrence-fre
interv rate recurr distant recurr
follow-up omiss adjuv chemotherapi howev rate invas disease-
free surviv overal surviv compar low
result preliminari model show excel concord initi
publish result tailorx trial outcom first five year patient
oncotyp score
conclus although recurr expect longer follow-up
model project show long-term recurr rate remain low among women
oncotyp score compet risk major driver morbid
mortal among women low risk recurr model simul use
extend clinic trial data synthes inform histor trial
persist circul tumor cell high risk earli breast cancer patient
five year adjuv chemotherapi late recurr result
background recent data suggest circul tumor cell prognost
relev earli well metastat breast cancer howev lack data
prognost impact predict late recurr long-term follow-
especi patient hormon receptor posit tumor
method success trial random phase studi patient
high-risk earli breast cancer first random cycl epirubicin-
fluorouracil-cyclophosphamid follow either cycl docetaxel cycl
gemcitabine-docetaxel follow second random vs year
zoledron treatment presenc year chemotherapi assess
use cellsearch system janssen diagnost llc ctc posit
defin ctc ml whole blood recurrence-fre surviv rf
analyz univari multivari cox regress surviv time
measur date blood sampl ctc assess
result follow-up data patient known ctc statu year
chemotherapi avail random patient median
diagnost tool
time interv ctc assess month sinc random ctc statu
posit patient rang median follow-up time
ctc assess day rang day overal late recurr
observ hormon receptor posit patient hormon
receptor neg patient hormon receptor posit patient ctc statu
signific prognost factor rf univari hazard ratio hr
confid interv ci multivari cox regress
adjust age tumor stage nodal stage grade histolog type statu
conclus presenc year chemotherapi associ
decreas rf suggest persist long term follow-up
independ predict late recurr hormon receptor posit patient
extend follow-up data present meet clinic trial
effect analysi oncotyp dx test patient
background oncotyp dx commerci diagnost test use predict like
benefit chemotherapi er node- breast cancer patient multipl
synchron ipsilater primari breast cancer often tumor test result
first tumor show low intermedi recurr score cost
effect unknown
method review oncotyp dx result breast cancer patient
histolog seen rush univers medic center
multipl synchron unilater tumor sampl test
result report numer risk score categor
low/intermediate/high recurr risk descript statist examin risk score
distribut assess potenti correl pair sampl cost
effect analysi perform calcul cost second test
subsequ treatment expect addit result
treatment deviat cost includ oncotyp test second tumor
cycl docetaxel cyclophosphamid recommend result
result concord rate risk categori patient
increas patient tumor histolog patient
tumor sampl low high rs gain addit life year patient
calcul use uk predict tool base averag tumor
characterist age patient cost adjuv therapi
addit oncotyp test divid assum increment cost
benefit ratio year yield cost per qali
conclus oncotyp dx test patient synchron unilater primari
breast cancer gener result concord result especi
histolog patient discord low/high tumor score taken
consider total cost test adjuv therapi small potenti
surviv benefit per qali standard test tumor
sampl patient synchron ipsilater breast cancer cost effect
diagnost tool
epic scienc cell left behind technolog help match patient therapi
monitor drug resist best treatment path chosen everi
clinic decis point epic scienc partner genom health ghdx buy
commerci oncotyp dx nucleu detect test help doc
make appropri therapeut decis prescrib either taxan
chemotherapi androgen-direct drug metastat castrat resist prostat
uniqu pattern select chang circul tumor cell ctc
phenotyp genotyp drug class metastat castration-resist
background biomark predict outcom individu patient pt standard
care rx unmet medic need treatment mcrpc use baselin bl
blood draw previous report phenotyp ctc heterogen algorithm
predict differenti surviv time arsi vs taxan also observ
certain gene alter well genom instabl link differ ctc
phenotyp subtyp sought associ ctc phenotyp respons
character phenotyp genotyp chang popul associ
select pressur specif drug class
method blood sampl match bl on-therapi uniqu
mcrpc pt collect process util epic scienc ctc platform
enumer character phenotyp includ ctc
subtyp pt receiv arsi therapi taxan
platinum contain regimen variou phenotyp subtyp
singl cell sequenc dna copi number variat
result detect bl
therapi sampl med median
respect chang ctc phenotyp featur observ uniqu specif
therapi class includ chang nuclear size shape textur persist ctc
phenotyp pt treat arsi taxan platinum enrich
cell ar over-express genom instabl pt
treat arsi taxan enrich loss
model predict resist therapi base specif ctc
preval earli on-therapi draw present
conclus observ broad ctc phenotyp genotyp heterogen prior
rx pattern clonal select specif differ standard care drug class
model util insight potenti predict resist observ pre-
therapi therapi enabl chang therapi prior clinic manifest
develop model on-going
analysi circul tumor cell patient across multipl
metastat breast cancer mbca cohort identifi mark inter- intra-
patient heterogen ctc size shape overal morpholog
background choic hormon therapi chemotherapi frequent
decis care mbca pt previous develop quantit measur
phenotyp ctc heterogen mcrpc found higher heterogen
associ better surviv chemotherapi vs target hormon therapi
revers true low heterogen patient scher et al cancer
diagnost tool
research sought appli previou heterogen quantit methodolog
cohort mbca patient ascertain feasibl mbca
method blood sampl mbca patient process ctc analysi
util epic scienc platform follow enumer multi-dimension
phenotyp character analysi perform util protein express
digit patholog featur featur ctc pt hr
tnbc compar unsupervis cluster
shannon index intra-pati varianc analys assess intra-pati
result detect mbca patient med
ctc/ml rang distinct ctc phenotyp identifi associ
mbca subtyp subset tnbc pt larger nuclear area higher ck
express vs subtyp addit observ mark differ
heterogen across patient patient rel uniform ctc
profil other high phenotyp divers mbca subtyp similar intra-
conclus distinct ctc phenotyp visual reproduc across patient
associ specif mbca subtyp analysi reveal signific
heterogen individu within patient
identif patient high heterogen may help find patient unlik
respond target therapi studi link heterogen therapeut efficaci
pt outcom on-going
propheci trial multicent prospect trial circul tumor cell
ctc detect men mcrpc receiv abirateron
background unclear ctc detect valid predict biomark
clinic efficaci men mcrpc receiv a/e indic aggress
diseas high tumor burden
method conduct multicent prospect studi circul biomark
men high-risk mcrpc propheci start a/e primari
endpoint associ baselin radiographic/clin progress free
surviv use john hopkin modified-adnatest ctc mrna assay
epic scienc ctc nuclear protein assay overal surviv os
declin key secondari endpoint
result enrol men mcrpc start a/e cellsearch
prior a/e studi therapi a/e ar-
detect jhu assay epic assay independ
associ wors os adjust ctc count establish
clinic factor see tabl concord two assay
epic men ctc phenotyp heterogen shannon
vs men epic men
found genet alter aggress mcrpc men
includ gain ar mycn myc loss dna repair
enzym ctdna
conclus valid detect independ ctc-adjust neg
predict biomark short os a/e treatment men mcrpc
identifi ctc heterogen express highlight import non-
driver aggress diseas clinic trial inform
diagnost tool
guardant commercial-stag liquid biopsi compani make strong traction
industri lead liquid biopsi test launch
liquid biopsi test perform oncologist list
price time sinc launch guardant
announc project lunar effort appli technolog platform
earli detect recurr monitor assess minim residu diseas
rais million may guardant rais
led softbank group set goal deploy test
peopl next year
opportun provid educ use interpret liquid
background increasingli afford comprehens genom profil cgp
exponenti expand amount data avail oncologist liquid biopsi
made cgp access given comprehens liquid biopsi
commerci avail sinc averag age practic oncologist
liquid biopsi educ compon major provid formal
train data commun academ set suggest physician
confid around interpret genom test may play critic role clinic
decis make physician knowledg also strong predictor physician
anticip use test although liquid biopsi gain popular
accept littl known provid confid interpret result
method prospect document provid call
test-rel question attempt character major theme
provid inquiri relat genom test liquid biopsi
result consecut provid contact record includ
complet survey data approx contact origin community-
base practic almost contact provid order
less test genom question specif liquid biopsi
provid question common question cfdna result includ
enough mutat present warrant treatment ideal time
test could mutat hereditari mutant allel
fraction mean interestingli provid survey question
regard basic genom principl specif liquid analysi remaind
question vari mani relat technolog
conclus provid commun academ center sought genom
support interpret comprehens liquid biopsi result question regard
gener genom liquid biopsi ask similar rate analysi
though liquid analysi emerg field data suggest still need
use cell-fre dna manag breast lung cancer academ
commun provid
background next-gener sequenc cell-fre dna cfdna assess
presenc somat genom alter patient cancer without invas
biopsi result may guid therapeut decision-mak evalu use cfdna
test result manag breast lung cancer major healthcar system
academ community-bas practic
diagnost tool
method retrospect review cfdna test order patient
breast lung cancer univers pittsburgh medic center
perform patient action result lung alter
fda-approv nccn-recommend target therapi breast
alter inform clinic care abstract differ clinic
use test result evalu academ commun provid
result total test order subject academ
commun provid commun provid order significantli
test lung cancer patient academ provid vs
patient older mean age vs yr action alter
identifi subject breast lung exclud
analys mutat known previous
remain subject action result led chang therapi
reason chang therapi includ patient die lost follow
therapi recommend cost prohibit patient current stabl result
could guid therapi progress action result significantli often
result manag chang lung cancer breast cancer vs
use test result differ significantli academ commun provid
result led chang vs
conclus result cfdna test use guid therapi chang especi
patient lung cancer commun practice-bas provid appear act
action result often academ center-bas provid health
evolut genom landscap circul tumor dna ctdna
advanc prostat cancer apc treatment time
background men apc respond initi treatment progress
requir sequenti therapi due advanc next-gener sequenc
feasibl assess tumor genom landscap via blood tumor tissu
differ time point treatment much debat exist concord tissu
tdna ctdna hypothes genom landscap apc evolv
treatment time howev pauciti experiment data support
statement exploratori analysi compar genom landscap
apc detect commerci avail tdna ctdna platform differ
point cours diseas
method men apc huntsman cancer institut univers utah
match tdna use foundationon foundat medicin cambridg
ctdna use inc redwood citi ca includ
clinic data collect retrospect exon region gene cover
platform includ analysi pair t-test use assess number
genom alter ga test platform confirm
nonparametr test number alter assess time number
treatment tdna ctdna test multivari nonparametr trend
result men apc match tissu ctdna includ
men new treatment year test similar number ga
detect test vs contrast men new
treatment test significantli ga treatment vs
total number ga correl number new treatment
test time test
diagnost tool
conclus hypothesis-gener data genom landscap apc
evolv subsequ therapi data suggest addit baselin
tumor genom profil contemporari tumor genom profil time diseas
landscap germlin somat revers alter
detect cell-fre dna test among patient metastat breast
ovarian pancreat prostat cancer
background parp inhibitor parpi shown efficaci breast bc ovarian oc
pancreat pac prostat prc cancer harbor deleteri germlin
somat alter alt gbrca sbrca addit acquir
revers alt rbrca restor open read frame orf report
set resist parpi platinum-bas chemotherapi next-
gener sequenc cell-fre dna cfdna provid platform evalu
rel frequenc three type brca alt pt advanc
method brca alt identifi among sampl pt
metastat bc oc pac prc tumor dna detect clinic cfdna
assay test run assay
evalu singl nucleotid variant indel track individu dna
molecul allow phase brca alt classifi gbrca
sbrca rbrcabas variant allel fraction vaf af neighbor germlin
rel posit alt sampl treatment histori obtain
test request form
result least one deleteri brca alt detect pt includ
pt bc oc pac prc patient
put gbrca alt addit alt consist rbrca bc
prc remain brca pt sbrca bc
multipl somat alt consist rbrca treatment histori avail
brca pt among indic exposur parpi
rbrca
conclus rate cfdna-detect gbrca sbrca alt pt advanc bc
oc pac compar report tcga higher among men prc
approxim half brca pt gbrca half sbrca highlight
valu cfdna test identifi type target brca alt
moreov rbrca identifi signific percentag brca pt
without foreknowledg germline- tissue-bas test may identifi pt
unlik respond parpi
foundat medicin fmi molecular inform compani offer
suit comprehens genom profil assay identifi molecular alter
patient cancer match relev target therapi
immunotherapi clinic trial foundat medicin offer foundationon
companion diagnost test next-gener sequenc base vitro diagnost
devic detect substitut insert delet alter indel
copi number alter cna gene select gene rearrang
well genom signatur includ microsatellit instabl tumor
mutat burden tmb use dna isol formalin-fix paraffin embed
diagnost tool
landscap kinas rearrang kre detect circul tumor dna
background kre establish oncogen driver therapeut target across
advanc cancer increasingli clinic activ target kre across tumor type
report larg base tissu analysi sought describ pan-canc
landscap predict driver kre identifi ctdna
method blood sampl cancer patient underw hybrid capture-bas
genom profil ctdna evalu rearrang gene egfr
pdgfra select intron bait other
braf pdgfrb sampl detect
ctdna includ analysi
result kre observ lung cancer lc case
non-lung nlc includ uniqu case overal
kre event tabl commonli rearrang kinas ret
egfr frequenc
kinas alter kre vari anatom origin event identifi
outsid lung cancer tabl top recurr kre lc
nlc
ret comparison tissu genom profil analyz
time period show ret kre ctdna tissu
lc sampl nlc ctdna tissu nlc kre detect
ctdna also detect pair tissu sampl includ
conclus kinas fusion rearrang exist across tumor type
detect liquid biopsi comparison genom profil ctdna tissu suggest
similar frequenc ret kre lung higher frequenc kre
non-lung sampl ctdna vs tissu perhap reflect greater heterogen
character nsclc egfr mutat
background exon delet classic activ egfrm
sensit approv tyrosin kinas inhibitor tki recent fda-approv
afatinib broaden includ rare egfrm
addit
method cgp perform nsclc sampl
tissu blood-bas ctdna patient pt posit
short variant egfrm pt profil pre- post-egfr tki includ variant
unknown signific exclud analysi tumor mutat burden
tmb determin mbp sequenc dna
result identifi egfrm nsclc case howev less
common egfrm includ exon indel
domain tmd kinas domain kd mutat frequent
mutat ecd tmd
kd-other
notabl differ pt age gender diseas histolog observ
subset except pt often femal vs egfrm
primari egfrm common case
tmd kd-other ecd rel
indel co-occur
diagnost tool
case egfrm case krasm co-occur
case case exon
indel kd-other egfr amplif present case
ecd kd-other remain egfrm
subset median tmb lowest mut/mb case
indel highest mut/mb case ecdm clinic outcom
present subset case
conclus divers egfrm repres almost egfrm
nsclc mani egfrm co-occur singl sampl may target
use current approv investig egfr tki
genom profil circul tumor dna ctdna patient pt
background tissu biopsi gold standard detect genom alter
ga select match target therapi nsclc ctdna assay provid
possibl complementari approach pt
method hybrid-captur base genom profil gene use ctdna assay
foundationact perform blood sampl consecut nsclc
pt fraction ctdna blood estim use maximum somat
allel frequenc msaf sampl
result pt characterist median age year rang femal
histolog includ adenocarcinoma nsclc otherwis specifi
sarcomatoid report ga detect case
case evid ctdna blood msaf pt pair
blood tissu sampl collect within day msaf ga
detect tissu also detect ctdna pt tissu
insuffici analysi ga detect ctdna case
case msaf averag ga/sampl report ga
frequent detect egfr kra compar
analysi tissue-bas foundationcor databas show
similar frequenc ga per gene although kra mutat frequent
tissu ctdna vs egfr frequent
ctdna tissu vs like reflect use liquid versu tissu
biopsi relaps target therapi kinas fusion ret
pdgfra identifi case divers novel mechan
acquir resist ar detect ctdna includ egfr
amplif post-crizotinib fusion post-egfr inhibitor multipl
conclus seri use rigor valid capture-bas assay reveal
evid ctdna blood case result provid clinic support
use assay complementari technolog tissue-bas genom test
subset pt nsclc
diagnost tool
genom profil circul tumor dna ctdna patient pt
background clonal evolut progress treatment mbc highlight
import genom profil recent sampl guid clinic decis
make undertook studi character genom alter ga ctdna
pt mbc cours clinic care
method hybrid-captur base genom profil gene foundationact
perform ctdna bc pt fraction ctdna blood
estim use maximum somat allel frequenc msaf sampl
result pt er unknown unk
er tripl neg tnbc unk er unk
stage pt treatment inform prior chemotherapi
er pt prior aromatas inhibitor therapi ai ga report
case case evid ctdna blood msaf
case msaf averag ga/cas report common ga
er pt kra
ga identifi pt er er unk
includ pt er pt treatment inform
prior ai ga pt ga prior ai pt ga
instanc ga ci frequent ga
rearrang amplif also detect
concurr ga found
er pt common ga
egfr activ mutat
occur case prior test kinas fusion
er egfr tnbc observ
conclus studi evid ctdna blood observ
case ga frequenc similar report previou
studi ctdna er pt ai divers ga co-occur ga suggest
therapeut approach ai refractori er mbc result demonstr
genom profil ctdna may complementari approach tissue-bas
genom test pt mbc
genom alter ga solid tumor hematolog
background amplif recent link
enhanc benefit immun checkpoint inhibitor icpi treatment use cgp
evalu ga landscap cancer
method specimen cancer repres individu diseas
ontolog sequenc use hybrid capture-bas next-gener sequenc
assay protein express measur immunohistochemistri
subset case use dako antibodi
result tumor ga ga
short variant sv truncat rearrang
co-amplifi sampl gene
commonli alter includ myc
tert sampl sv ga
common tert ga sampl sv ga missens
compar truncat splice site ga recurr somat
diagnost tool
variant unknown signific vu observ includ frameshift
missens ga may regul stabil common tumor breast
lung carcinoma ca repres case select
cancer notabl frequenc anaplast thyroid ca head
neck squamou ca hnscc cervic scc breast lung
bladder ca common tumor type colorect pancreat
ovarian prostat ca melanoma glioblastoma
strong correl express nsclc
posit sampl show stain posit
stain major clinic respons icpi therapi tumor
present
conclus ga occur rare across mani cancer type mani
somat ga uncharacter vu correl high
membran express measur link durabl respons
icpi therapi evalu potenti biomark
genom alter mesothelioma potenti predictor
background swi/snf famili modul chromatin
remodel genom alter ga enrich renal cell carcinoma
mesothelioma ms recent evid suggest ga strongli
associ neoantigen product respons immun checkpoint
method comprehens genom profil cgp perform ng dna
next-gener sequenc assay median coverag depth result
analyz class ga tumor mutat burden tmb determin
mb dna microsatellit instabl statu evalu
princip compon analysi optim homopolym loci ga count
relev known disrupt homozyg tumor
result relapsed/refractori ms pericardi pcdm
periton perm pleural plrm tumor tabl median age
similar specimen male common plrm
femal perm ga frequenc overal
plrm perm ga found ms
ga wild type ms ga ga
median tmb low tmb mut/mb uncommon
instanc ms high ms patient ga respond
icpi treatment present
conclus immunotherapi strategi treatment ms recent
emerg ga seen ms repres potenti predict
biomark therapi select typic devast diseas studi
statu icpi treatment ms clinic trial set appear
diagnost tool
genom fast-grow privat held commercial-stag genom platform
compani enabl research discov first time new structur variant
haplotyp import genom inform use exist sequenc
technolog enabl research call phase structur variant
obtain long rang info short read genom host
booth technolog featur abstract year
promot colorect cancer screen multiplex genet test
genet counsel
background cancer screen guidelin recommend germlin carrier
pathogen variant pv suscept gene undergo frequent
colonoscopi screen assess impact genet counsel multiplex
genet panel test mgpt adher colonoscopi screen
method prospect cohort studi patient undergo mgpt patient
completed-self-administ questionnair document colon cancer screen
within one year test patient survey month genet
result disclosur multivari logist regress use analyz associ
